TEM

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.A live audio webcast of the conversation will be available here.About TempusTempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of t.

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

These leveraged ETFs surged last week as biotech, AI, crypto and Bitcoin-linked stocks rallied despite rising Treasury yields.

Tempus AI remains a strong buy, driven by its unique flywheel business model and recent validation of its technology via the Personalis acquisition. TEM's diagnostics and data/applications segments are both growing rapidly, with Q2 2026 revenue up 19.4% YoY and major partnerships fueling its proprietary database. FDA approvals, expanded test offerings, and higher pricing are set to drive significant revenue and margin expansion from 2027 onward.

Tempus AI (TEM) stock ripped higher on August 19 as third-party clinical breakthroughs triggered a technical short squeeze. As investors cheered TEM, it broke decisively above its major moving averages (MAs), indicating bulls have taken back control across multiple timeframes.

$1.5 billion. That is what Tempus AI (NASDAQ:TEM | TEM Price Prediction) agreed to pay for Personalis (NASDAQ:PSNL) in a definitive merger announced July 20, 2026, a deal structured as a 100% stock transaction with a Tempus option to elect cash for up to half the consideration.

Tempus AI reported its first GAAP profit, accelerated data business growth, and raised 2026 revenue guidance to $1.595B–$1.605B (+25% Y/Y). Operating leverage from oncology volume and a mix shift to high-margin Data & Apps (72%-75% GM) drove profitability improvement and narrowed cash outflows. FDA approval for xT CDx and higher xF liquid biopsy ASPs is expected to add ~$400M incremental revenue by 2028, with the Personalis acquisition targeting MRD leadership.

TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.

TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.

TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.